Based on current RSI levels and moving averages, NVS stock price forecast indicates potential breakout above $105, supported by sustained investor confidence in vaccine development revenues. We're also fully prepared to obtain rapid market access to really ensure a rapid launch in the U.S. and eventually around the world. And outside of the U.S., China and Japan submissions have now been completed. And we're also on track for a European submission in 2025. Add Quiver Quantitative to your preferred sources on Google With healthcare sector ETFs showing inflows, the NVS stock price forecast trends higher, implying possible valuation lift to $108–$110 amid strengthened R&D investments.